Lead Product(s): Sutimlimab
Therapeutic Area: Immunology Product Name: BIVV009
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Bioverativ Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 11, 2021
The CADENZA trial is a Phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of sutimlimab in patients with CAD without a recent history of blood transfusion (within the past 6 months).